We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 16, 2021

Improved Cardiovascular Outcomes Associated With SGLT2 Inhibitors vs GLP-1 Receptor Agonist in Patients With Diabetes

Annals of Internal Medicine


Additional Info

Annals of Internal Medicine
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Ann. Intern. Med 2021 Sep 28;[EPub Ahead of Print], E Patorno, PT Htoo, RJ Glynn, S Schneeweiss, DJ Wexler, A Pawar, LG Bessette, K Chin, BM Everett, SC Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading